...
  • 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Hematology >Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia
【24h】

Preventing and monitoring for tumor lysis syndrome and other toxicities of venetoclax during treatment of chronic lymphocytic leukemia

机译：慢性淋巴细胞白血病治疗过程中肿瘤裂解综合征和威胁综合征和其他毒性的预防和监测

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Recent developments in the management of chronic lymphocytic leukemia (CLL) have moved the standard of care away from chemoimmunotherapy to targeted agents such as oral kinase inhibitors or BCL-2 antagonists, alone or in combination with anti-CD20 antibodies. Two different treatment approaches have evolved: continuous, indefinite treatment and, more recently, fixed-duration combination treatment. With venetoclax-based treatment, there is a requirement to follow the established guidelines for close monitoring during initiation and ramp up, to reduce the risk of tumor lysis syndrome. The patient’s risk should be assessed before the initiation of venetoclax. Appropriate management strategies should be used, including uricosuric agents, hydration, and routine laboratory monitoring, per guidelines. With early identification, immediate management, and dose adjustments, we suggest that tumor lysis syndrome and other toxicities, such as neutropenia and infections, with venetoclax-based treatment can be dealt with successfully.
机译：在慢性淋巴细胞性白血病（CLL）的管理的最新发展已经移动的护理标准从化学免疫治疗，以靶向药物远，例如口服激酶抑制剂或BCL-2拮抗剂，单独地或与抗CD20抗体的组合。两种不同的治疗方法已经演变：连续的，不确定的治疗，最近，固定时间联合治疗。基于venetoclax治疗，有跟随启动过程中密切监测既定的方针和斜坡上升，以减少肿瘤溶解综合征的风险的要求。病人的风险应该venetoclax开始前进行评估。适当的管理策略应采用，包括排尿酸药，水化和常规实验室监测，每准则。随着早期识别，直接管理，并调整剂量，我们认为肿瘤溶解综合征等不良反应，如白细胞减少和感染，与基于venetoclax处理可以处理成功。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号